Employees Retirement System of Texas Makes New $953,000 Investment in Zimmer Biomet Holdings, Inc. $ZBH

Employees Retirement System of Texas acquired a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 10,600 shares of the medical equipment provider’s stock, valued at approximately $953,000.

A number of other hedge funds and other institutional investors have also modified their holdings of ZBH. Border to Coast Pensions Partnership Ltd boosted its position in shares of Zimmer Biomet by 6.5% during the 3rd quarter. Border to Coast Pensions Partnership Ltd now owns 360,462 shares of the medical equipment provider’s stock worth $35,506,000 after acquiring an additional 22,104 shares in the last quarter. National Pension Service raised its position in shares of Zimmer Biomet by 4.5% during the 3rd quarter. National Pension Service now owns 393,476 shares of the medical equipment provider’s stock worth $38,757,000 after acquiring an additional 16,928 shares in the last quarter. AMG National Trust Bank lifted its stake in Zimmer Biomet by 29.1% during the third quarter. AMG National Trust Bank now owns 50,359 shares of the medical equipment provider’s stock worth $4,960,000 after purchasing an additional 11,339 shares during the last quarter. Skandinaviska Enskilda Banken AB publ boosted its holdings in Zimmer Biomet by 47.5% in the third quarter. Skandinaviska Enskilda Banken AB publ now owns 62,079 shares of the medical equipment provider’s stock valued at $6,115,000 after purchasing an additional 19,996 shares in the last quarter. Finally, New York State Common Retirement Fund increased its stake in Zimmer Biomet by 24.9% in the third quarter. New York State Common Retirement Fund now owns 208,503 shares of the medical equipment provider’s stock valued at $20,538,000 after purchasing an additional 41,538 shares during the last quarter. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have issued reports on ZBH shares. BTIG Research restated a “neutral” rating on shares of Zimmer Biomet in a research note on Monday, March 23rd. Barclays cut their target price on Zimmer Biomet from $100.00 to $94.00 and set an “underweight” rating on the stock in a research report on Wednesday, April 29th. Truist Financial reissued a “hold” rating and issued a $92.00 target price (down from $98.00) on shares of Zimmer Biomet in a research report on Wednesday, April 29th. UBS Group reaffirmed a “sell” rating and set a $89.00 price target on shares of Zimmer Biomet in a research report on Wednesday, February 11th. Finally, Weiss Ratings upgraded Zimmer Biomet from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, April 7th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $102.80.

Zimmer Biomet Price Performance

Zimmer Biomet stock opened at $82.58 on Thursday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.73 and a quick ratio of 0.95. The business has a 50 day simple moving average of $88.28 and a 200-day simple moving average of $90.73. Zimmer Biomet Holdings, Inc. has a 12 month low of $79.12 and a 12 month high of $108.29. The stock has a market capitalization of $15.98 billion, a PE ratio of 21.45, a price-to-earnings-growth ratio of 1.95 and a beta of 0.48.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.86 by $0.23. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. The company had revenue of $2.09 billion for the quarter, compared to analysts’ expectations of $2.07 billion. During the same period in the previous year, the company posted $1.81 EPS. Zimmer Biomet’s revenue was up 9.3% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. Equities analysts predict that Zimmer Biomet Holdings, Inc. will post 8.47 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Thursday, June 25th will be issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 1.2%. The ex-dividend date of this dividend is Thursday, June 25th. Zimmer Biomet’s payout ratio is currently 24.94%.

Insiders Place Their Bets

In other Zimmer Biomet news, SVP Lori Winkler sold 2,650 shares of the business’s stock in a transaction that occurred on Thursday, March 12th. The stock was sold at an average price of $94.66, for a total transaction of $250,849.00. Following the transaction, the senior vice president owned 10,224 shares in the company, valued at approximately $967,803.84. The trade was a 20.58% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 1.28% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.